Umbilical Cord Mesenchymal Stem Cell-Derived Extracellular Vesicles as Natural Nanocarriers in the Treatment of Nephrotoxic Injury In Vitro.

Autor: Convento MB; Nephrology Division, Department of Medicine, Federal University of Sao Paulo, Sao Paulo 04038-901, Brazil., de Oliveira AS; Nephrology Division, Department of Medicine, Federal University of Sao Paulo, Sao Paulo 04038-901, Brazil., Boim MA; Nephrology Division, Department of Medicine, Federal University of Sao Paulo, Sao Paulo 04038-901, Brazil., Borges FT; Nephrology Division, Department of Medicine, Federal University of Sao Paulo, Sao Paulo 04038-901, Brazil.; Interdisciplinary Postgraduate Program in Health Sciences, Cruzeiro do Sul University, Sao Paulo 01506-000, Brazil.
Jazyk: angličtina
Zdroj: Cells [Cells] 2024 Oct 07; Vol. 13 (19). Date of Electronic Publication: 2024 Oct 07.
DOI: 10.3390/cells13191658
Abstrakt: Umbilical cord mesenchymal stem cell-derived extracellular vesicles (UC-EVs) are valuable in nanomedicine as natural nanocarriers, carrying information molecules from their parent cells and fusing with targeted cells. miRNA-126, specific to endothelial cells and derived from these vesicles, supports vascular integrity and angiogenesis and has protective effects in kidney diseases.
Objective: This study investigates the delivery of miRNA-126 and anti-miRNA-126 via UC-EVs as natural nanocarriers for treating nephrotoxic injury in vitro.
Method: The umbilical cord-derived mesenchymal stem cell and UC-EVs were characterized according to specific guidelines. Rat kidney proximal tubular epithelial cells (tubular cells) were exposed to nephrotoxic injury through of gentamicin and simultaneously treated with UC-EVs carrying miRNA-126 or anti-miRNA-126. Specific molecules that manage cell cycle progression, proliferation cell assays, and newly synthesized DNA and DNA damage markers were evaluated.
Results: We observed significant increases in the expression of cell cycle markers, including PCNA, p53, and p21, indicating a positive cell cycle regulation with newly synthesized DNA via BrDU. The treatments reduced the expression of DNA damage marker, such as H2Ax, suggesting a lower rate of cellular damage.
Conclusions: The UC-EVs, acting as natural nanocarriers of miRNA-126 and anti-miRNA-126, offer nephroprotective effects in vitro. Additionally, other components in UC-EVs, such as proteins, lipids, and various RNAs, might also contribute to these effects.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje